| First Author | Kabeya H | Year | 1999 |
| Journal | Vet Immunol Immunopathol | Volume | 68 |
| Issue | 1 | Pages | 39-48 |
| PubMed ID | 10231950 | Mgi Jnum | J:56213 |
| Mgi Id | MGI:1340432 | Doi | 10.1016/s0165-2427(99)00005-7 |
| Citation | Kabeya H, et al. (1999) Bovine leukaemia virus envelope peptides cause immunomodulation in BALB/c mice. Vet Immunol Immunopathol 68(1):39-48 |
| abstractText | Immunomodulatory activity of two bovine leukaemia virus envelope (BLVEnv) derived peptides were examined in BALB/c mice. One is peptide homologous to CKS-17 which is known as a 17-amino acid peptide derived from p15E of feline leukaemia virus (CKS-17/BLV), and the other is an 18-amino acid synthetic peptide of BLV Env 61-78 (pep61). Priming with CKS-17/BLV in vitro, as well as CKS-17, significantly suppressed the mitogen-induced proliferative responses of spleen cells in naive BALB/c mice. In addition, priming of spleen cells with pep61 in vitro and in vivo resulted in suppression of lipopolysaccaride-induced B-cell proliferative response. This suppression was partially due to the basic amino acid sequence in the peptide because if the pep61-derived peptide lacking Arg was used, this inhibitory activity was partially restored. In contrast, pep61 enhanced both concanavalin A-stimulated proliferative response and IL-2 production. These findings showed that pep61 may contribute to the modification of the host immune responses in the course of BLV infection. |
